Topiramate for juvenile myoclonic epilepsy

CONCLUSIONS: We have found no new studies since the last version of this review was published in 2019. This review does not provide sufficient evidence to support topiramate for the treatment of people with JME. Based on the current limited available data, topiramate seems to be better tolerated than valproate, but has no clear benefits over valproate in terms of efficacy. Well-designed, double-blind RCTs with large samples are required to test the efficacy and tolerability of topiramate in people with JME.PMID:34817852 | DOI:10.1002/14651858.CD010008.pub5
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Source Type: research